Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease

NCT03977584 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: Crenezumab
DRUG: Placebo
OTHER: [^18F]GTP1

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]
[object Object]